Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. More Details
Very undervalued with flawless balance sheet.
Share Price & News
How has Cipher Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CPH is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CPH's weekly volatility (11%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CPH underperformed the Canadian Pharmaceuticals industry which returned 65.6% over the past year.
Return vs Market: CPH exceeded the Canadian Market which returned 34.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cipher Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StAnalysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)
1 month ago | Simply Wall StCipher Pharmaceuticals Inc.'s (TSE:CPH) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
2 months ago | Simply Wall StCipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next
Is Cipher Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CPH (CA$1.65) is trading below our estimate of fair value (CA$9.27)
Significantly Below Fair Value: CPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CPH is good value based on its PE Ratio (11x) compared to the Canadian Pharmaceuticals industry average (22.6x).
PE vs Market: CPH is good value based on its PE Ratio (11x) compared to the Canadian market (14.7x).
Price to Earnings Growth Ratio
PEG Ratio: CPH is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: CPH is good value based on its PB Ratio (1x) compared to the CA Pharmaceuticals industry average (3.2x).
How is Cipher Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CPH's forecast earnings growth (13.6% per year) is above the savings rate (1.5%).
Earnings vs Market: CPH's earnings (13.6% per year) are forecast to grow slower than the Canadian market (13.9% per year).
High Growth Earnings: CPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: CPH's revenue is expected to decline over the next 3 years (-4.8% per year).
High Growth Revenue: CPH's revenue is forecast to decline over the next 3 years (-4.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CPH's Return on Equity is forecast to be high in 3 years time
How has Cipher Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CPH has a large one-off loss of $6.7M impacting its March 31 2021 financial results.
Growing Profit Margin: CPH's current net profit margins (15.4%) are lower than last year (18.5%).
Past Earnings Growth Analysis
Earnings Trend: CPH's earnings have declined by 2.7% per year over the past 5 years.
Accelerating Growth: CPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CPH had negative earnings growth (-24.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.1%).
Return on Equity
High ROE: CPH's Return on Equity (9.6%) is considered low.
How is Cipher Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CPH's short term assets ($22.4M) exceed its short term liabilities ($10.7M).
Long Term Liabilities: CPH's short term assets ($22.4M) exceed its long term liabilities ($1.7M).
Debt to Equity History and Analysis
Debt Level: CPH is debt free.
Reducing Debt: CPH has no debt compared to 5 years ago when its debt to equity ratio was 66.4%.
Debt Coverage: CPH has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CPH has no debt, therefore coverage of interest payments is not a concern.
What is Cipher Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CPH's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Craig J. Mull has been Chairman of the Board of Directors at Cipher Pharmaceuticals Inc. since June 11, 2019 and its Interim Chief Executive Officer since July 29, 2019, served as its President. Mr. Mu...
Experienced Management: CPH's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: CPH's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CPH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cipher Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cipher Pharmaceuticals Inc.
- Ticker: CPH
- Exchange: TSX
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$44.187m
- Shares outstanding: 26.78m
- Website: https://www.cipherpharma.com
Number of Employees
- Cipher Pharmaceuticals Inc.
- 209 Oak Park Boulevard
- Suite 501
- L6H 0M2
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/19 02:30|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.